Advanced Artificial Intelligence Technologies Transforming Contemporary Pharmaceutical Research
- PMID: 40281723
- PMCID: PMC12024664
- DOI: 10.3390/bioengineering12040363
Advanced Artificial Intelligence Technologies Transforming Contemporary Pharmaceutical Research
Abstract
One area of study within machine learning and artificial intelligence (AI) seeks to create computer programs with intelligence that can mimic human focal processes in order to produce results. This technique includes data collection, effective data usage system development, conclusion illustration, and arrangements. Analysis algorithms that are learning to mimic human cognitive activities are the most widespread application of AI. Artificial intelligence (AI) studies have proliferated, and the field is quickly beginning to understand its potential impact on medical services and investigation. This review delves deeper into the pros and cons of AI across the healthcare and pharmaceutical research industries. Research and review articles published throughout the last few years were selected from PubMed, Google Scholar, and Science Direct, using search terms like 'artificial intelligence', 'drug discovery', 'pharmacy research', 'clinical trial', etc. This article provides a comprehensive overview of how artificial intelligence (AI) is being used to diagnose diseases, treat patients digitally, find new drugs, and predict when outbreaks or pandemics may occur. In artificial intelligence, neural networks and deep learning are some of the most popular tools; in clinical research, Bayesian non-parametric approaches hold promise for better results, while smartphones and the processing of natural languages are employed in recognizing patients and trial monitoring. Seasonal flu, Ebola, Zika, COVID-19, tuberculosis, and outbreak predictions were made using deep computation and artificial intelligence. The academic world is hopeful that AI development will lead to more efficient and less expensive medical and pharmaceutical investigations and better public services.
Keywords: artificial intelligence; computational learning; drug discovery; healthcare; patient; personalized medicine; structural activity relationship.
Conflict of interest statement
The authors declare no conflict of interest.
Figures









Similar articles
-
Opportunities and challenges in application of artificial intelligence in pharmacology.Pharmacol Rep. 2023 Feb;75(1):3-18. doi: 10.1007/s43440-022-00445-1. Epub 2023 Jan 9. Pharmacol Rep. 2023. PMID: 36624355 Free PMC article. Review.
-
Artificial Intelligence Revolution in Pharmaceutical Sciences: Advancements, Clinical Impacts, and Applications.Curr Pharm Biotechnol. 2025 Jan 23. doi: 10.2174/0113892010356115241224104018. Online ahead of print. Curr Pharm Biotechnol. 2025. PMID: 39851128
-
Combating COVID-19 Crisis using Artificial Intelligence (AI) Based Approach: Systematic Review.Curr Top Med Chem. 2024;24(8):737-753. doi: 10.2174/0115680266282179240124072121. Curr Top Med Chem. 2024. PMID: 38318824
-
Artificial intelligence in drug development: reshaping the therapeutic landscape.Ther Adv Drug Saf. 2025 Feb 24;16:20420986251321704. doi: 10.1177/20420986251321704. eCollection 2025. Ther Adv Drug Saf. 2025. PMID: 40008227 Free PMC article. Review.
-
Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery.Cureus. 2023 Aug 30;15(8):e44359. doi: 10.7759/cureus.44359. eCollection 2023 Aug. Cureus. 2023. PMID: 37779744 Free PMC article. Review.
References
-
- Dastha J.F. Application of artificial intelligence to pharmacy and medicine. Hospital. 1992;27:312–315, 319–322. - PubMed
-
- Duch W., Swaminathan K., Meller J. Artificial intelligence approaches for rational drug design and discovery. Curr. Pharm. Des. 2007;13:1497–1508. - PubMed
-
- Scannell J.W., Blanckley A., Boldon H., Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012;11:191200. - PubMed
-
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009;8:95968. - PubMed
-
- Mak K.K., Pichika M.R. Artificial intelligence in drug development: Present status and future prospects. Drug Discov. Today. 2019;24:773–780. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous